Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $21.6 million.

  • PAVmed's Shares Outstanding (Diluted Average) changed N/A to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year change of. This contributed to the annual value of $65.3 million for FY2024, which is 80287.23% up from last year.
  • Latest data reveals that PAVmed reported Shares Outstanding (Diluted Average) of $21.6 million as of Q3 2025.
  • PAVmed's Shares Outstanding (Diluted Average)'s 5-year high stood at $89.8 million during Q3 2022, with a 5-year trough of $5.9 million in Q4 2022.
  • Its 4-year average for Shares Outstanding (Diluted Average) is $32.5 million, with a median of $9.2 million in 2024.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first crashed by 9199.99% in 2023, then soared by 80287.23% in 2024.
  • PAVmed's Shares Outstanding (Diluted Average) (Quarter) stood at $5.9 million in 2022, then increased by 21.78% to $7.2 million in 2023, then surged by 802.87% to $65.3 million in 2024, then crashed by 66.99% to $21.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $21.6 million in Q3 2025, compared to $54.3 million in Q2 2025 and $52.5 million in Q1 2025.